rituximab,Efgartigimod
argenx
['ritux']
#ash22 broome: efgartigamod favored in all subgroups. no concerning aes with efgartigamod: less bleeding (71 v 87%) and slightly higher risk of infection (29 v 22%). 
Assoc Professor, UCSF hematology/BMT. Translational researcher interested in leukemia, MDS, MRD, post-HCT relapse, GVHD, & immune recon. Photos: pyknosis (IG)